Cyclerion Therapeutics (NASDAQ:CYCN) Issues Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings results on Tuesday. The company reported $0.22 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $1.81 million for the quarter.

Cyclerion Therapeutics Trading Down 8.0 %

Cyclerion Therapeutics stock opened at $2.42 on Thursday. Cyclerion Therapeutics has a 12-month low of $1.27 and a 12-month high of $9.47. The firm’s fifty day moving average is $3.15 and its 200 day moving average is $2.92.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.